ArticleNature genetics2009
Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.
Article in Nature genetics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 131 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
131 citing papers in PubMed, 9 syntheses or guidelines pooled it, 326 citations in OpenAlex.
- Pharmacogenetics of chemotherapy treatment response and -toxicities in patients with osteosarcoma: a systematic review.BMC cancer · 2022Pooled it
- Different infusion durations for preventing platinum-induced hearing loss in children with cancer.The Cochrane database of systematic reviews · 2020Pooled it
- Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.The Cochrane database of systematic reviews · 2019Pooled it
- The genetic vulnerability to cisplatin ototoxicity: a systematic review.Scientific reports · 2019Pooled it
- Different infusion durations for preventing platinum-induced hearing loss in children with cancer.The Cochrane database of systematic reviews · 2018Pooled it
- TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity.Pharmacogenetics and genomics · 2017Pooled it
- Platinum-induced hearing loss after treatment for childhood cancer.The Cochrane database of systematic reviews · 2016Pooled it
- Pooled it
- Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations.The pharmacogenomics journal · 2013Pooled it
- Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer.PloS one · 2019Trial
- Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children With Cerebral Palsy.PM & R : the journal of injury, function, and rehabilitation · 2018Trial
- Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: report from the Children's Oncology Group.Pediatric blood & cancer · 2014Trial
- Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients.Pediatric blood & cancer · 2012Trial
- Trial
- Pharmacogenetics in Community Pharmacy: Global Perspectives and Implementation.Journal of clinical medicine · 2026Review
- Navigating the Genetic Risk of Chemotherapy-Induced Hearing Loss in the Stria Vascularis.Clinical pharmacology and therapeutics · 2026Review
- Comedication that increase the risk of cisplatin-induced hearing loss in pediatric cancer patients: a narrative literature review and meta-analysis.Frontiers in oncology · 2026Review
- Uncovering position-specific patterns in codon and codon-pair usage in candidate genes associated with blood coagulation diseases.NAR genomics and bioinformatics · 2025Article
- Article
- Determination of a New Biomarker at the Level of Gene Alteration in Cisplatin Ototoxicity.International journal of molecular sciences · 2025Article
71 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
15 authors at 5 institutions in 1 country.
Funding
Abstract
Cisplatin is a widely used and effective chemotherapeutic agent, although its use is restricted by the high incidence of irreversible ototoxicity associated with it. In children, cisplatin ototoxicity is a serious and pervasive problem, affecting more than 60% of those receiving cisplatin and compromising language and cognitive development. Candidate gene studies have previously reported associations of cisplatin ototoxicity with genetic variants in the genes encoding glutathione S-transferases and megalin. We report association analyses for 220 drug-metabolism genes in genetic susceptibility to cisplatin-induced hearing loss in children. We genotyped 1,949 SNPs in these candidate genes in an initial cohort of 54 children treated in pediatric oncology units, with replication in a second cohort of 112 children recruited through a national surveillance network for adverse drug reactions in Canada. We identified genetic variants in TPMT (rs12201199, P value = 0.00022, OR = 17.0, 95% CI 2.3-125.9) and COMT (rs9332377, P value = 0.00018, OR = 5.5, 95% CI 1.9-15.9) associated with cisplatin-induced hearing loss in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.